Clinical Research of Licartin Combined With TACE in the Treatment of Unresectable Hepatocellular Carcinoma
Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
Liver cancer is a highly invasive malignancy and the rate of surgical resection is no more
than 28%. After diagnosis, the average survival rate of patient is less than 50% in 6 month,
less than 24% in 1 year and 5% in 5 year. The TACE treatment, under the theoretical basis of
blood supply of Liver cancer, is obviously better than the other non-surgical therapy, in
terms of tumor regression, AFP decrease, survival time and the evaluation of the quality of
life. However, its overall effect is not yet satisfactory. As a result, concerning the
research of drug for liver cancer and improving the overall efficacy of the treatment of
liver cancer has a very real and important clinical significance and social value. Licartin
(Iodine-131-Labeled Metuximab) injection is a antibody drug with new target and the only drug
that China own the intellectual property rights. It has specific high affinity with
HAb18G/CD147, the liver cell membrane antigen. Labeled 131I is taken to the liver tissue,
owning high-dose concentration and releasing β particles to liver cancer cells to and kill
cancer cells.
The Second Military Medical University, Eastern Hepatobiliary Surgery Hospital, planed to use
the treatment of Licartin combined with TACE for the patients of unresectable hepatocellular
carcinoma and evaluate the difference of tumor size, AFP change, TTP, the overall survival
rate between different treatment group.